• profileicon
  • contacticon
  • emailicon

2023 pharma predictions

Submitted by darshana.sawant on

The pandemic continued to affect supply chains, inflation was at a recent all-time high, and FDA approvals hit a five-year low. The Inflation Reduction Act was signed into law back in August, promising to limit the pharma industry’s pricing power.

Despite these tests, the industry experienced pivotal moments. Humira’s patent expiration led to CDER’s 40th biosimilar approval — with more to follow. There was a surge of gene therapy approvals, including the first gene therapy for hemophilia B.

Looking into the OSD Crystal Ball: Industry Experts Reflect on Opportunities & Challenges in '23 & Beyond

Submitted by darshana.sawant on

The Future of Quality in Manufacturing

The next decade will see pharmaceutical companies change their manufacturing ecosystems with emphasis on product quality, speed to market, efficiency, waste reduction, cost containment and skill retention to meet regulatory and consumer demands. To achieve this, companies are embarking on a digital transformation journey towards a new manufacturing strategy, a concept called Pharma 4.0., to achieve their competitive advantage.